Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2459
Title: Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates
Authors: Tomaske, M.
Geraerds, Ajlm
van Herk, W.
Stocker, M.
El Helou, S.
Dutta, S.
Fontana, M. S.
Schuerman, Faba
van den Tooren-de Groot, R. K.
Wieringa, J.
Janota, J.
van der Meer-Kappelle, L. H.
Moonen, R.
Sie, S. D.
de Vries, E.
Donker, A. E.
Zimmerman, U.
Schlapbach, L. J.
de Mol, A. C.
Hoffman-Haringsma, A.
Roy, M.
Kornelisse, R. F.
van Gijsel, J.
Visser, E. G.
van Rossum, A. M. C.
Polinder, S.
Issue Date: 2021
Source: Oct 20 25, (1), 2021, p. 367
Pages: 367
Journal: Crit Care
Abstract: BACKGROUNDS: The large, international, randomized controlled NeoPInS trial showed that procalcitonin (PCT)-guided decision making was superior to standard care in reducing the duration of antibiotic therapy and hospitalization in neonates suspected of early-onset sepsis (EOS), without increased adverse events. This study aimed to perform a cost-minimization study of the NeoPInS trial, comparing health care costs of standard care and PCT-guided decision making based on the NeoPInS algorithm, and to analyze subgroups based on country, risk category and gestational age. METHODS: Data from the NeoPInS trial in neonates born after 34 weeks of gestational age with suspected EOS in the first 72 h of life requiring antibiotic therapy were used. We performed a cost-minimization study of health care costs, comparing standard care to PCT-guided decision making. RESULTS: In total, 1489 neonates were included in the study, of which 754 were treated according to PCT-guided decision making and 735 received standard care. Mean health care costs of PCT-guided decision making were not significantly different from costs of standard care (€3649 vs. €3616). Considering subgroups, we found a significant reduction in health care costs of PCT-guided decision making for risk category 'infection unlikely' and for gestational age ≥ 37 weeks in the Netherlands, Switzerland and the Czech Republic, and for gestational age < 37 weeks in the Czech Republic. CONCLUSIONS: Health care costs of PCT-guided decision making of term and late-preterm neonates with suspected EOS are not significantly different from costs of standard care. Significant cost reduction was found for risk category 'infection unlikely,' and is affected by both the price of PCT-testing and (prolonged) hospitalization due to SAEs.1466-609xGeraerds, A J L M
Orcid: 0000-0002-1332-0500
van Herk, Wendy
Stocker, Martin
El Helou, Salhab
Dutta, Sourabh
Fontana, Matteo S
Schuerman, Frank A B A
van den Tooren-de Groot, Rita K
Wieringa, Jantien
Janota, Jan
van der Meer-Kappelle, Laura H
Moonen, Rob
Sie, Sintha D
de Vries, Esther
Donker, Albertine E
Zimmerman, Urs
Schlapbach, Luregn J
de Mol, Amerik C
Hoffman-Haringsma, Angelique
Roy, Madan
Tomaske, Maren
Kornelisse, René F
van Gijsel, Juliette
Visser, Eline G
van Rossum, Annemarie M C
Polinder, Suzanne
Journal Article
Crit Care. 2021 Oct 20;25(1):367. doi: 10.1186/s13054-021-03789-x.
DOI: 10.1186/s13054-021-03789-x
Keywords: Procalcitonin-guided decision making;Neonates;Sepsis;*Anti-Bacterial Agents/therapeutic use*Clinical Decision-Making/methods;*Duration of Therapy;Early Diagnosis;*Health Care Costs/statistics & numerical data;Humans;Infant, Newborn;Procalcitonin/blood;*Sepsis/diagnosis/drug therapy;Costs
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

58
checked on Mar 13, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.